期刊文献+

八珍汤加味防治肺癌术后化疗毒性反应98例 被引量:3

98 cases of Prevention and Treatment of Lung Cancer after Chemotherapy Toxicity Bazhen Decoction
下载PDF
导出
摘要 [目的]探讨八珍汤加味对肺癌术后化疗引起化疗毒性反应的临床疗效。[方法]将98例肺癌术后患者随机分为治疗组和对照组,每组49例,治疗组服八珍汤加味(黄芪、党参、茯苓、白术、川芎、熟地、当归、白芍等);对照组给予常规对症治疗,不服用中药,进行疗效观察。[结果]治疗组化疗毒性反应各项均较对照组减轻,两组间比较有显著差异(P<0.01);治疗组Karnofsky评分提高稳定率93.9%,两组间比较有显著差异(P<0.01)。[结论]八珍汤加味防治肺癌术后化疗毒性反应具有较好疗效。 [ Objective ] To investigate the clinical efficacy of postoperative chemotherapy of lung cancer caused by chemotherapy toxicity Bazhen decoction. [ Method] 98 cases of lung cancer after patients were ran- domly divided into treatment and control group,49 cases in each treatment group service the the decoction Bazhen (Huangqi, Dangshen, Fuling, Baizhu, Chuanxiong, Shudi, Danggui, Baishao, et al. ) ; The control group received conventional symptomatic treatment, not taking medicine, effects were observed. [ Results ] treatment group, chemotherapy toxicity of various than in the control group to reduce a significant difference between the two groups ( P 〈 0.01 ) ; Karnofsky score of the treatment group to improve the stability rate of 93. 9% ,there are significant differences between the two groups (P 〈0.01 ). [ Conclusion] Bazhen Tonga taste prevention and treatment of lung cancer after chemotherapy toxicity reaction with good effect.
出处 《实用中医内科杂志》 2012年第9期74-75,共2页 Journal of Practical Traditional Chinese Internal Medicine
关键词 肺癌术后 八珍汤 化疗毒副反应 KS评分 中医药疗法 lung cancer after Bazhen decoction side effects of chemotherapy KS score TraditionalChinese medicine treatment
  • 相关文献

参考文献3

二级参考文献38

共引文献87

同被引文献45

  • 1孙燕,石远凯.临床肿瘤内科手册[M].第5版,北京:人民卫生出版社,2008:711-717.
  • 2王永炎.中医内科学[M].上海:上海科技出版社,1998.58—72.
  • 3Briccoli A,Rocca M,Salone M,et al.High grade osteosarcoma of the extremities metastatic to the lung:long-term results in 323patients treated combining surgery and chemotherapy,1985-2005[J].Surg Oncol,2010,19(4):193-199.
  • 4Endo-Munoz L.,Cumming A.,Sommerville S.,et al.Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone[J].British journal of cancer,2010,103:73-81.
  • 5Jaffe N.Osteosarcbma:Review of the past,impact on the future.Thmerican experience[J].Cancer Treat Res,2010,152:239-262.
  • 6Mirabello,L,Troisi,R.J.&Savage,S.A.Osteosarcoma incidence and survival rates from 1973 to 2004:data from the Surveillance,Epidemiology,and End Results Program[J].Cancer,2009,115:1531-1543.
  • 7Parkes S.E.,Parke S.,Mangham D.C.,et al.Fifty years of paediatric malignant bone tumours in the West Midlands,UK,1957-2006:incidence,treatment and outcome[J].Paediatric and perinatal epidemiology,2010,24:470-478.
  • 8Meyers PA,Schwartz CL,Krailo MD,et al.Osteosarcoma:the addition of muramyl tripeptide to chemotherapy improves overall survival:a report from the Children's Oncology Group[J].J Clin Oncol,2008,26(4):633-638.
  • 9Sampo M.,Koivikko M.,Taskinen M.,et al.Incidence,epidemiology and treatment results of osteosarcoma in Finland-a nationwide population-based study[J].Acta Oncol,2011,50:1206-1214.
  • 10Longhi A,Ferrari S,Bacci G,et al.Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma[J].Anticancer Drugs,2007,72(3-4):255-260.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部